The company has developed a multiplex panel for bacterial and yeast infections that it plans to submit for FDA clearance in 2027.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback